1. Structural basis of potent Zika-dengue virus antibody cross-neutralization
- Author
-
Franz X. Heinz, Juthathip Mongkolsapaya, Ahmed Haouz, Arvind Sharma, Patrick England, Van-Mai Cao-Lormeau, Wanwisa Dejnirattisai, Félix A. Rey, Anavaj Sakuntabhai, Iris Medits, Etienne Simon-Loriere, Gavin R. Screaton, Karin Stiasny, Alexander Rouvinski, Giovanna Barba-Spaeth, Marie Christine Vaney, Virologie Structurale - Structural Virology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Division of Immunology and Inflammation, Department of Medicine, Imperial College London-Hammersmith Hospital Campus, Medizinische Universität Wien = Medical University of Vienna, Génétique fonctionnelle des Maladies infectieuses - Functional Genetics of Infectious Diseases, Emerging Infectious Diseases, Institut Louis Malardé [Papeete] (ILM), Institut de Recherche pour le Développement (IRD)-Institut de Recherche pour le Développement (IRD), Cristallographie (Plateforme) - Crystallography (Platform), Biophysique des Macromolécules et de leurs Interactions, Siriraj Hospital, Mahidol University, Mahidol University [Bangkok], We acknowledge support from the European Commission FP7 Programme for the DENFREE project under Grant Agreement number 282 378FP7 (F.A.R., J.M., G.R.S. and A.Sa.), the 'Integrative Biology of Emerging Infectious Diseases' Labex (Laboratoire d’Excellence) grant number ANR-10-LABX-62-IBEID (French Government’s 'Investissements d’Avenir' program ) (F.A.R.), the transnational ANR/FWF grant FlaviStem/I1378 (F.A.R. and K.S.), the Medical Research Council, UK (J.M.), the National Institute for Health Research Biomedical Research Centre, Funding Scheme, UK (G.R.S.), and the NEUTRAVIR grant from Région ile-de-France (DIM-Maladies Infectieuses) (P.E., A.H. and F.A.R., ANR-13-ISV8-0002,flavistem,La protéine E des flavivirus : interactions et fusion membranaire(2013), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 282378,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,DENFREE(2012), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Medical Research Council (MRC), Wellcome Trust, and Commission of the European Communities
- Subjects
DYNAMICS ,0301 basic medicine ,Models, Molecular ,viruses ,[SDV]Life Sciences [q-bio] ,Antigen-Antibody Complex ,Dengue virus ,medicine.disease_cause ,Crystallography, X-Ray ,Epitope ,Zika virus ,Dengue fever ,Dengue ,Epitopes ,0302 clinical medicine ,Viral Envelope Proteins ,INFECTION ,Virus maturation ,IN-VIVO ,FLAVIVIRUSES ,Phylogeny ,Multidisciplinary ,Zika Virus Infection ,Antibodies, Monoclonal ,REACTIVE ANTIBODIES ,FUSION-LOOP ,3. Good health ,Multidisciplinary Sciences ,Flavivirus ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Science & Technology - Other Topics ,Brazil ,General Science & Technology ,Dengue Vaccines ,Biology ,Cross Reactions ,MATURATION ,Microbiology ,03 medical and health sciences ,ENHANCEMENT ,medicine ,Humans ,Antibody-dependent enhancement ,Dengue vaccine ,Science & Technology ,RECEPTOR ,RECOGNITION ,Viral Vaccines ,Zika Virus ,Dengue Virus ,biology.organism_classification ,medicine.disease ,Virology ,Antibodies, Neutralizing ,030104 developmental biology ,030217 neurology & neurosurgery - Abstract
International audience; Zika virus is a member of the Flavivirus genus that had not been associated with severe disease in humans until the recent outbreaks, when it was linked to microcephaly in newborns in Brazil and to Guillain-Barré syndrome in adults in French Polynesia. Zika virus is related to dengue virus, and here we report that a subset of antibodies targeting a conformational epitope isolated from patients with dengue virus also potently neutralize Zika virus. The crystal structure of two of these antibodies in complex with the envelope protein of Zika virus reveals the details of a conserved epitope, which is also the site of interaction of the envelope protein dimer with the precursor membrane (prM) protein during virus maturation. Comparison of the Zika and dengue virus immunocomplexes provides a lead for rational, epitope-focused design of a universal vaccine capable of eliciting potent cross-neutralizing antibodies to protect simultaneously against both Zika and dengue virus infections.
- Published
- 2016
- Full Text
- View/download PDF